When do the patents on ROCEPHIN expire, and when will generic ROCEPHIN be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ROCEPHIN	ceftriaxone sodium	INJECTABLE;INJECTION	062654-002	Apr 30, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hoffmann La Roche	ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER	ceftriaxone sodium	INJECTABLE;INJECTION	050624-002	Feb 11, 1987		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hoffmann La Roche	ROCEPHIN	ceftriaxone sodium	INJECTABLE;INJECTION	063239-002	Aug 13, 1993		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hoffmann La Roche	ROCEPHIN	ceftriaxone sodium	INJECTABLE;INJECTION	050585-005	Dec 21, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hoffmann La Roche	ROCEPHIN	ceftriaxone sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	050585-004	Dec 21, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 17, 2026

ROCEPHIN (ceftriaxone) investment scenario and fundamentals analysis: patent/launch risk, competitive landscape, and revenue durability

Rocephin (ceftriaxone, IV/IM) is a mature, off-patent large-volume injectable with global availability of multiple generic and biosimilar-equivalent competitors in most markets. The investment case is therefore driven less by exclusivity and more by (1) supply resilience for an older beta-lactam, (2) formulation and manufacturing cost advantages, (3) contract execution in hospital procurement, and (4) regulatory and IP exposure from the remaining product- and process-level patent thickets in specific geographies.

Bottom line: For new entrants, “patent life” is not the primary value lever for ceftriaxone; cost, supply chain, and distribution are. For existing branded holders or investors in manufacturing platforms, returns hinge on maintaining reliability of supply and defending any remaining country-specific formulations, concentrations, or packaging IP.

What is Rocephin (ceftriaxone) and how does it fit in hospital antimicrobial use?

Featured snippet answer: Rocephin is ceftriaxone, a third-generation cephalosporin used for severe bacterial infections in hospitals and outpatient settings where IV/IM therapy is appropriate, with demand concentrated in acute care, surgical prophylaxis-adjacent regimens, and community-acquired infection pathways where clinicians favor broad coverage.

Which infections drive ceftriaxone demand?

Key clinical indications for ceftriaxone typically include:

Community-acquired pneumonia (CAP)
Complicated intra-abdominal infections (as part of combination regimens)
Skin and soft tissue infections (selected cases)
Urinary tract infections (UTI), including pyelonephritis
Bacterial meningitis
Septicemia/sepsis (in combination and depending on local stewardship protocols)
Bone and joint infections (selected settings)
Sexually transmitted infection syndromes in guideline-directed therapy (country dependent)
Surgical prophylaxis in select surgical services (guideline and local formulary dependent)

Why ceftriaxone persists despite resistance pressure

Ceftriaxone remains a mainstay because it offers:

Long dosing interval (commonly once daily in many regimens)
Predictable PK for routine hospital use
Extensive lab familiarity and guideline embedding
Broad bacterial coverage relative to older cephalosporins

What are the key drivers and risks in the ROCEPHIN (ceftriaxone) commercial model?

Featured snippet answer: Commercial performance for ceftriaxone is driven by hospital formulary position, procurement tender outcomes, seasonal infection patterns, and global antibiotic substitution behavior; risks are drug shortages, price erosion from generics, and stewardship-driven utilization shifts.

Demand drivers

Acute care bed days: Higher admissions increase injectable antibiotic throughput.
Clinical pathway adherence: Order sets and local antibiograms influence ceftriaxone selection.
Supply reliability: Hospitals prefer products with dependable availability for IV/IM antibiotics.

Core risks

Price compression: Generic entrants drive rapid price erosion.
Procurement bundling: Large group purchasing organizations (GPOs) and tenders can force low price.
Antimicrobial stewardship: Increased restriction can reduce routine use.
Supply chain disruptions: API and sterile filling capacity constraints affect continuity.

Where margins realistically come from

For an off-patent antibiotic, sustained economics usually come from:

Manufacturing scale and yield
Lower cost of goods (COGS) for ceftriaxone sodium and sterile reconstitution supply chain
Contract pricing leverage through consistent delivery and QA track record
Diversified packaging and concentration SKUs that fit tender templates

What is the Orange Book status of Rocephin (ceftriaxone) in the US?

Featured snippet answer: Ceftriaxone products are broadly off-exclusivity in the US, with no meaningful remaining branded exclusivity barrier for generic ceftriaxone for most dosage forms and strengths; any remaining value is typically in product-specific IP that is not a general entry wall.

How to read the practical exclusivity landscape

Older antibiotics often have legacy patents that expired years ago.
Any surviving IP for a specific product configuration is commonly tied to:
- specific strengths,
- specific manufacturing/process steps,
- or packaging and labeling details.

Which patents protect Rocephin (ceftriaxone), and how fast do they expire?

Featured snippet answer: The patent estate around ceftriaxone has largely matured into an expired or near-expired structure; for investment, remaining patents tend to be narrow and jurisdiction-specific, so entry risk is usually short-window rather than multi-year.

Typical patent categories that can still matter

Even when the active ingredient is off patent, residual protection can exist for:

Manufacturing processes (process patents for impurity profiles and crystallization controls)
Formulation or sterile filling methods (specific lyophilized vs powder for reconstitution formats, excipient choices)
Methods of use (often weak for generics unless still tied to an enforceable claim set)

Investor implication

If the investment thesis assumes “patent life,” the thesis is usually misaligned with ceftriaxone’s market structure. Returns typically depend on:

cost and supply,
tender execution,
and any remaining process/IP moat tied to validated impurity specs.

When does ROCEPHIN lose exclusivity, and how does that affect generic entry timing?

Featured snippet answer: Ceftriaxone’s broad drug substance exclusivity is effectively already expired in major markets; any remaining exclusivity windows, where they exist, are generally tied to specific product generations and have limited impact on current generic entry horizons.

Paragraph IV or ANDA timing relevance

For widely available injectables like ceftriaxone, the market often has already-penetrated ANDA supply.
New ANDA entry timing tends to be driven by manufacturing readiness and regulatory approval rather than brand exclusivity.

What generic entry risks exist for Rocephin in the US and major EU markets?

Featured snippet answer: Entry risks are mainly execution risks (approval, manufacturing capacity, sterile QA, API access) and tender dynamics, not legal barriers.

US risk profile (commercial)

Rapid price declines post-approval of additional generic suppliers.
Contracts shift volume to the lowest delivered cost with acceptable quality.

EU and UK risk profile (commercial)

Similar procurement-driven price compression.
Local market tendering and multiple-supplier frameworks reduce single-brand bargaining power.

How strong is the patent estate for ceftriaxone, and does it create defensible revenue?

Featured snippet answer: For Rocephin, the patent estate does not typically create durable defensibility at the brand level. Any remaining enforceable value is narrow and operational, not product-level monopoly.

What “defensibility” looks like when patents are weak

Defensibility can come from:

validated sterile manufacturing lanes,
supply agreements for hospital networks,
and consistent compliance outcomes.

What patent litigation affects ceftriaxone, and does it matter for investment?

Featured snippet answer: Ongoing litigation is usually not the main driver of ceftriaxone economics because the molecule is largely off exclusivity and generic availability is widespread; where litigation exists, it tends to be about narrow process/formulation claims with limited incremental market protection.

How to evaluate litigation relevance for Rocephin

Even without detailed case-by-case inputs, the investment screen is:

Is the litigation aimed at blocking supply of a major strength/form factor?
Does it delay volume for a meaningful subset of tenders?
Are there settlement terms that carve out specific launch dates or supply limits?

For a mature injectable, unless litigation creates a near-term exclusivity carve-out, it rarely changes the long-run competitive baseline.

What formulations are protected by product-specific patents for Rocephin?

Featured snippet answer: Any formulation-level protection is typically confined to specific product presentations rather than the drug substance. In practice, the market is largely saturated across standard ceftriaxone presentations (IV/IM powders for reconstitution).

Practical formulation differentiation that affects procurement

Powder strength and vial configuration
Reconstitution volume and administration workflow
Stability and impurity profile targets
Sterile and packaging compatibility with hospital pharmacy handling

How does Rocephin compare with competing antibiotics in hospital contracting?

Featured snippet answer: Ceftriaxone faces competition on broad-spectrum cephalosporins and other guideline-preferred options (penicillins, fluoroquinolones where appropriate, carbapenems in severe resistance settings), but procurement and stewardship often favor ceftriaxone for cost-effective coverage.

Where competitors displace ceftriaxone

Resistance patterns and antibiogram-driven selection
Treatment of atypical or resistant organisms where other classes dominate
Preference for alternatives with different dosing schedules or safety profiles in local stewardship protocols

Where ceftriaxone holds share

Hospitals needing reliable once-daily IV/IM options
Standard treatment pathways for common bacterial infections
Settings where formularies emphasize established antibiotic use

Commercial outlook: how durable is Rocephin demand and pricing?

Featured snippet answer: Demand durability is high for ceftriaxone because it is entrenched in hospital infection pathways; pricing durability is low due to generic competition and tender-driven erosion.

Revenue durability scenarios

Base case: stable unit demand with declining ASP as more suppliers compete.
Downside: utilization declines from stewardship restrictions or volume shift to alternatives.
Upside: supply constraints among competitors or new manufacturing capacity enabling tender wins at competitive pricing.

What investors should track (leading indicators)

Hospital tender results and contract awards
Shortage or allocation events
API price movements and sterile fill capacity constraints
Changes in guideline pathways and formulary restrictions

What is the competitive landscape for ceftriaxone injectables?

Featured snippet answer: Competition is primarily among generic manufacturers of ceftriaxone sodium, with additional competition from other broad-spectrum beta-lactams and alternative antibiotics; market share rotates via procurement rather than differentiation.

Typical competitive set behavior

Multiple approved generic suppliers compete on:
- delivered price,
- fill reliability,
- and documentation packages demanded by hospital procurement.

Investment scenario playbooks: where can investors find value in ceftriaxone?

Featured snippet answer: Value is most investable through manufacturing platforms, supply chain reliability, and contract execution, not through exclusive IP monetization.

Scenario A: Manufacturer/infrastructure investment

Invest in sterile manufacturing capacity, QA systems, and yield improvement.
Objective is lower COGS and fewer batch rejects.
Licensing opportunities can exist via API supply or sterile fill partnerships.

Scenario B: Supply chain and contract-focused strategy

Target hospital networks and regional wholesalers where consistent allocation matters.
Monetize reliability premiums during shortage periods.

Scenario C: Portfolio investing (antibiotic basket)

Ceftriaxone is a stable-demand anchor.
Returns are driven by hedged exposure across antibiotics with different supply-demand dynamics.

What regulatory considerations affect Rocephin market access and risk?

Featured snippet answer: Regulatory risk centers on sterile product quality systems, CMC updates, impurity management, and inspection outcomes. For an off-patent generic-heavy market, regulatory execution can be the gating factor.

Key regulatory risk areas

Sterility assurance and aseptic processing controls
Impurity specifications and batch consistency
Labeling and reconstitution instructions compliance
Stability and packaging validation
Inspection history and corrective action timelines

Key Takeaways

Patent-driven exclusivity is not the core Rocephin value lever; ceftriaxone is mature and largely off exclusivity in major markets.
Commercial durability is driven by entrenched hospital use, not by brand protection.
Pricing and margins are tender- and supply-chain dependent; unit volumes can remain steady while ASP erodes.
Investment returns track manufacturing reliability, COGS, and contract execution, plus the ability to prevent supply interruptions.
Litigation and remaining narrow patents rarely change the long-run competitive baseline for ceftriaxone, absent a specific settlement or injunction affecting a meaningful strength/form factor.

FAQs

1) Is Rocephin still prescribed in the era of newer antibiotics?
Yes, ceftriaxone remains used where broad coverage and practical once-daily dosing fit hospital infection pathways.

2) Do ceftriaxone generics substitute for the branded product immediately?
In most markets, yes, substitution is routine after regulatory approval, and procurement typically favors the lowest delivered cost with acceptable quality.

3) What typically causes ceftriaxone shortages or allocation?
API supply constraints, sterile fill capacity limits, batch failures tied to impurity control, and regulatory quality actions.

4) Are there major differences in safety or efficacy between Rocephin and generics?
Generics are required to meet bioequivalence and CMC standards; clinically, differences are usually related to handling, reconstitution workflow, and stability rather than core efficacy.

5) What is the best investment thesis for an off-patent injectable like Rocephin?
Invest in manufacturing scale, compliance excellence, and supply reliability aligned with hospital contracting cycles.

References

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
World Health Organization. (n.d.). Antimicrobial resistance and antibiotic stewardship resources. WHO.
FDA Labeling and Drug Approval Resources. (n.d.). Drug information for ceftriaxone products. FDA.

US Patents:	0
Applicants:	2
NDAs:	5

AI Deep Research

Questions you can ask:

Summary for ROCEPHIN